226950 — OliX Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- KR₩934bn
- KR₩962bn
- KR₩6bn
Annual income statement for OliX Pharmaceuticals, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,474 | 3,674 | 9,320 | 17,064 | 5,677 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 18,716 | 27,614 | 31,696 | 34,828 | 44,291 |
| Operating Profit | -16,241 | -23,939 | -22,376 | -17,764 | -38,614 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20,511 | -29,997 | -29,108 | -18,170 | -41,071 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -19,385 | -29,176 | -28,113 | -19,102 | -40,659 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -19,385 | -29,715 | -19,495 | -19,102 | -40,659 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -19,385 | -29,715 | -19,495 | -19,102 | -40,659 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,474 | -2,099 | -1,878 | -1,339 | -2,181 |
| Dividends per Share |